Tryngolza (olezarsen) is an antisense oligonucleotide drug developed for treating familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely high triglyceride levels.
It is indicated for adult patients with FCS who have not achieved sufficient triglyceride control through diet and other lipid - lowering therapies. Eligibility typically requires confirmation of the genetic mutation underlying FCS and a clinical profile consistent with severe hypertriglyceridemia. As with all prescription medications, use should be initiated and monitored by a healthcare provider experienced in managing rare lipid disorders, considering individual patient factors and potential contraindications.

